GNI Group (2160) AI Stock Analysis

• Market Cap: €140.80B
• Dividend Yield: N/A
• Average Volume (3M): 969.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 2.04%
• EPS Growth: -102.04%
• Country: JP
• Employees: 867
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.62
• Shares Outstanding: 55,608,833
• 10 Day Avg. Volume: 1,104,200
• 30 Day Avg. Volume: 969,156
• PEG Ratio: -2.00
• Price to Book (P/B): 4.67
• Price to Sales (P/S): 7.21
• P/FCF Ratio: -46.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: ¥2,291.00 ▼(-8.76% Downside)

The overall stock score is primarily impacted by financial performance challenges, including negative profitability and cash flow issues. Technical analysis further indicates bearish momentum, while valuation metrics highlight significant concerns with a negative P/E ratio and no dividend yield.

GNI Group Business Overview & Revenue Model

Company Description

GNI Group (2160) is a prominent player in the biotechnology and pharmaceutical sectors, primarily focused on the development and manufacturing of biopharmaceutical products. The company specializes in drug discovery, development, and production, offering a range of services that cater to the needs of global pharmaceutical companies. GNI Group is particularly known for its expertise in the production of active pharmaceutical ingredients (APIs) and its commitment to innovative solutions in biotechnology.

How the Company Makes Money

GNI Group generates revenue primarily through the sale of its biopharmaceutical products and services, including the production of active pharmaceutical ingredients (APIs) for various therapeutic areas. The company's revenue model is bolstered by long-term contracts and collaborations with major pharmaceutical companies, which provide a steady stream of income. Additionally, GNI Group benefits from research and development partnerships that enhance its product offerings and market reach. The company may also earn revenue from licensing agreements and royalties associated with its proprietary technologies and innovations in the biotech field.

GNI Group Financial Statement Overview

Summary

The company faces profitability and cash flow challenges, with a negative net profit margin and deteriorating cash generation, despite a strong gross profit margin and manageable leverage.

Income Statement

The income statement shows a mixed performance. The TTM data indicates a gross profit margin of 75.8%, which is strong, but the net profit margin is negative at -4.38%, reflecting recent profitability challenges. Revenue growth is positive at 4.99% TTM, but EBIT and EBITDA margins have turned negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet is relatively stable with a low debt-to-equity ratio of 0.19 TTM, suggesting manageable leverage. However, the return on equity is negative at -2.87% TTM, indicating inefficiencies in generating returns from equity. The equity ratio is not provided, but the overall leverage appears controlled.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows TTM. The free cash flow growth rate is -19.72%, indicating deteriorating cash generation. The operating cash flow to net income ratio is negative, highlighting cash flow issues relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.13B	23.61B	26.01B	17.42B	12.69B	9.77B
Gross Profit	17.30B	18.04B	22.43B	14.74B	11.09B	8.23B
EBITDA	105.29M	2.39B	14.49B	2.16B	2.14B	2.19B
Net Income	-267.85M	977.66M	8.09B	388.82M	1.07B	1.26B
Balance Sheet
Total Assets	67.72B	71.94B	62.39B	33.91B	30.30B	23.22B
Cash, Cash Equivalents and Short-Term Investments	10.52B	12.93B	23.15B	11.25B	14.36B	10.34B
Total Debt	4.86B	7.21B	3.70B	537.36M	1.13B	1.75B
Total Liabilities	29.41B	32.23B	26.34B	14.10B	11.03B	10.45B
Stockholders Equity	35.27B	36.45B	33.79B	20.97B	18.86B	11.00B
Cash Flow
Free Cash Flow	-3.03B	-3.69B	4.47B	-1.55B	-142.13M	1.02B
Operating Cash Flow	-2.63B	-3.16B	6.55B	393.32M	552.27M	1.38B
Investing Cash Flow	-918.42M	-10.36B	-6.84B	-4.12B	-260.64M	570.21M
Financing Cash Flow	-999.41M	694.16M	10.69B	-646.33M	2.85B	801.12M

GNI Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2511.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2160, the sentiment is Positive. The current price of 2511 is above the 20-day moving average (MA) of 2436.80, above the 50-day MA of 2494.94, and below the 200-day MA of 2825.68, indicating a neutral trend. The MACD of 2.27 indicates Negative momentum. The RSI at 53.57 is Neutral, neither overbought nor oversold. The STOCH value of 70.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2160.

GNI Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4974	55 Neutral	¥109.94B	190.54	―	1.86%	6.98%	406.15%
4587	53 Neutral	$198.76B	-39.40	-9.08%	―	-65.56%	-123.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4592	48 Neutral	$204.92B	-56.23	-252.15%	―	―	-58.12%
2160	44 Neutral	€140.80B	-889.83	-0.47%	―	2.04%	-102.04%
4565	41 Neutral	$72.67B	-11.78	-9.05%	―	-1.96%	-64.18%
4593	41 Neutral	¥53.92B	―	―	―	-78.54%	10.23%

GNI Group Corporate Events

GNI Group’s Subsidiary Completes Enrollment for Key Clinical Trial

GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has completed subject enrollment for a Phase 3 clinical trial of Pirfenidone Capsule, aimed at treating pneumoconiosis. This trial, conducted across 18 centers in China, evaluates the drug’s efficacy and safety over 52 weeks. The completion of enrollment marks a significant step in the development of treatments for this chronic lung disease, although the financial impact on GNI Group’s current fiscal year is expected to be minimal.

The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group Advances Non-Opioid Pain Therapy with Phase 1 Trial Completion

GNI Group Ltd. announced the completion of subject enrollment for the Phase 1 clinical trial of CG001419, a novel non-opioid pain product candidate developed by its subsidiary Cullgen. This trial marks a significant step in offering a new class of pain signal inhibitors that could provide safer and more effective treatment options for acute and chronic pain, with plans to advance to Phase 2 trials by early next year. The financial impact on the company’s current fiscal year is expected to be minimal.

The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group Ltd. Expands Global Presence Through Strategic Equity Offering

GNI Group Ltd. has conducted an overseas equity offering to raise growth capital, aiming to enhance its global market presence and attract international institutional investors. This strategic move is part of the company’s flexible capital strategy to support long-term shareholder value and accelerate growth. The funds will be used to explore M&A opportunities and further develop its drug portfolio, including the F351 product for liver fibrosis, while maintaining a balanced approach to future financing options.

The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group Appoints New Executive Officer to Drive Global Growth

GNI Group Ltd. has appointed Takuya Kaneko as Executive Officer and Chief Strategy Officer, effective August 28, 2025, to strengthen its global management structure and pursue sustainable growth. Kaneko’s extensive experience in investment banking and biotechnology is expected to aid the company in expanding its revenue base in Japan and advancing its global healthcare strategies, benefiting stakeholders and contributing to the healthcare industry’s advancement.

The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2735.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group Reports Q2 FY2025 Financial Results with Increased Revenue but Net Loss

GNI Group Ltd. reported its consolidated financial results for the second quarter of fiscal year 2025, showing a 4.4% increase in revenue compared to the previous year. However, the company experienced a decline in operating income and pre-tax profit, resulting in a net loss for the period. This financial performance may impact the company’s market positioning and stakeholder confidence as it navigates challenges in the pharmaceutical industry.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group Increases Stake in Gyre Pharmaceuticals to Boost Corporate Value

GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has acquired additional shares in Gyre Pharmaceuticals, increasing its equity interest to 69.72%. This strategic move aims to minimize profit outflows to minority shareholders and enhance the Group’s corporate value, particularly as Gyre Pharmaceuticals is set to handle the entire value chain for a new liver fibrosis drug candidate. The acquisition is expected to positively impact the Group’s financial results, although the exact effect is still under review.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.